Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (3) : 265-270    https://doi.org/10.1007/s11684-009-0055-0
Research articles
MicroRNAs and hepatitis viruses
Gang LI MD , Xiaojia XIONG MM ,
Department of Infectious Diseases, The Third Affiliated Hospital of Sun-Yat Sen University, Guangzhou 510630, China;
 Download: PDF(107 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract MicroRNAs (miRNAs) are a class of small RNA molecules. They play a pivotal role in diverse domains such as infection, tumorigenesis, and immune reaction. As key regulators of most genes’ expression, they react at posttranscriptional level. It is increasingly clear that miRNAs are necessary for physiological and pathological processes. In the past few years, investigators gradually brought the concept of miRNA into studies of viral infection, including hepatitis viruses. The hepatitis B and C viruses are common causes of liver disease worldwide. It is very difficult to cure chronic hepatitis due to drug resistance during antivirus therapy. Elucidating the mechanisms of virus-host interactions in hepatitis B and C is very important in diagnosis, prognosis, and therapy. This article reviews the current knowledge of viral hepatitis (B and C type) at the level of miRNA and tries to outline areas of potential studies.
Keywords microRNA      hepatitis B virus      hepatitis C virus      
Issue Date: 05 September 2009
 Cite this article:   
Gang LI MD,Xiaojia XIONG MM. MicroRNAs and hepatitis viruses[J]. Front. Med., 2009, 3(3): 265-270.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0055-0
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I3/265
Lee Y, Kim M, Han J, Yeom K H, Lee S, Baek S H, Kim V N. MicroRNA genes are transcribedby RNA polymerase II. EMBO J, 2004, 23(20): 4051―4060

doi: 10.1038/sj.emboj.7600385
Lund E, Güttinger S, Calado A, Dahlberg J E, Kutay U. Nuclear export of microRNAprecursors. Science, 2004, 303(5654): 95―98

doi: 10.1126/science.1090599
Gottwein E, Cullen B R. Viral and cellular microRNAsas determinants of viral pathogenesis and immunity. Cell Host Microbe, 2008, 3(6): 375―387

doi: 10.1016/j.chom.2008.05.002
Ghosh Z, Mallick B, Chakrabarti J. Cellular versus viral microRNAs in host-virus interaction. Nucleic Acids Res, 2009, 37(4): 1035―1048

doi: 10.1093/nar/gkn1004
Yu Z, Jian Z, Shen S H, Purisima E, Wang E. Global analysis of microRNAtarget gene expression reveals that miRNA targets are lower expressedin mature mouse and Drosophila tissues than in the embryos. Nucleic Acids Res, 2007, 35(1): 152―164

doi: 10.1093/nar/gkl1032
Sun R, Fu X, Li Y, Xie Y, Mao Y. Global gene expression analysis revealsreduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics, 2009, 10: 93

doi: 10.1186/1471-2164-10-93
Schmittgen T D, Lee E J, Jiang J, Sarkar A, Yang L, Elton T S, Chen C. Real-time PCRquantification of precursor and mature microRNA. Methods, 2008, 44(1): 31―38

doi: 10.1016/j.ymeth.2007.09.006
Rajewsky N. MicroRNAtarget predictions in animals. Nat Genet, 2006, 38(Suppl): S8―13

doi: 10.1038/ng1798
Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG. The database of experimentallysupported targets: a functional update of TarBase. Nucleic Acids Res, 2009, 37(Database issue): D155―158

doi: 10.1093/nar/gkn809
Canales R D, Luo Y, Willey J C, Austermiller B, Barbacioru C C, Boysen C, Hunkapiller K, Jensen R V, Knight C R, Lee K Y, Ma Y, Maqsodi B, Papallo A, Peters E H, Poulter K, Ruppel P L, Samaha R R, Shi L, Yang W, Zhang L, Goodsaid F M. Evaluation of DNA microarrayresults with quantitative gene expression platforms. Nat Biotechnol, 2006, 24: 1115―1122

doi: 10.1038/nbt1236
Arikawa E, Sun Y, Wang J, Zhou Q, Ning B, Dial SL, Guo L, Yang J. Cross-platform comparison of SYBR Green real-time PCRwith TaqMan PCR, microarrays and other gene expression measurementtechnologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics, 2008, 9: 328

doi: 10.1186/1471-2164-9-328
Cullen B R. Viruses and microRNAs. Nat Genet, 2006, 38(Suppl): S25―30

doi: 10.1038/ng1793
Jin W B, Wu F L, Kong D, Guo A G. HBV-encodedmicroRNA candidate and its target. ComputBiol Chem, 2007, 31(2): 124―126

doi: 10.1016/j.compbiolchem.2007.01.005
Li Z, Zhang S, Huang C, Zhang W, Hu Y, Wei B. MicroRNAomeof splenic macrophages in hypersplenism due to portal hypertensionin hepatitis B virus-related cirrhosis. Exp Biol Med (Maywood), 2008, 233(11): 1454―1461

doi: 10.3181/0711-RM-321
Gao Y F, Yu L, Wei W, Li J B, Luo Q L, Shen J L. Inhibition of hepatitis B virus gene expression and replication byartificial microRNA. World J Gastroenterol, 2008, 14(29): 4684―4689

doi: 10.3748/wjg.14.4684
Esau C, Davis S, Murray S F, Yu X X, Pandey S K, Pear M, Watts L, Booten S L, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. MiR-122 regulationof lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 2006, 3(2): 87―98

doi: 10.1016/j.cmet.2006.01.005
Shan Y, Zheng J, Lambrecht R W, Bonkovsky H L. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1and hepatitis C virus genes in human hepatocytes. Gastroenterology, 2007, 133(4): 1166―1174

doi: 10.1053/j.gastro.2007.08.002
Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. Diagnostic assay based onhsa-miR-205 expression distinguishes squamous from nonsquamous non-small-celllung carcinoma. J Clin Oncol, 2009, 27(12): 2030―2037

doi: 10.1200/JCO.2008.19.4134
Merritt W M, Lin Y G, Han L Y, Kamat A A, Spannuth W A, Schmandt R, Urbauer D, Pennacchio L A, Cheng J F, Nick A M, Deavers M T, Mourad-Zeidan A, Wang H, Mueller P, Lenburg M E, Gray J W, Mok S, Birrer M J, Lopez-Berestein G, Coleman R L, Bar-Eli M, Sood A K. Dicer, Drosha, and outcomesin patients with ovarian cancer. N EnglJ Med, 2008, 359(25): 2641―2650

doi: 10.1056/NEJMoa0803785
Slack F J, Weidhaas J B. MicroRNA in cancer prognosis. N Engl J Med, 2008, 359(25): 2720―2722

doi: 10.1056/NEJMe0808667
O'Donnell K A, Wentzel E A, Zeller K I, Dang C V, Mendell J T. c-Myc-regulated microRNAs modulate E2F1expression. Nature, 2005, 435(7043): 839―843

doi: 10.1038/nature03677
Liu Y, Zhao J J, Wang C M, Li M Y, Han P, Wang L, Cheng Y Q, Zoulim F, Ma X, Xu D P. Altered expression profiles of microRNAsin a stable hepatitis B virus-expressing cell line. Chin Med J (Engl), 2009, 122(1): 10―14
Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNAprofiling in hepatocellular tumors is associated with clinical featuresand oncogene/tumor suppressor gene mutations. Hepatology, 2008, 47(6): 1955―1963

doi: 10.1002/hep.22256
Wong Q W, Lung R W, Law P T, Lai P B, Chan K Y, To K F, Wong N. MicroRNA-223 is commonlyrepressed in hepatocellular carcinoma and potentiates expression ofStathmin1. Gastroenterology, 2008, 135(1): 257―269

doi: 10.1053/j.gastro.2008.04.003
Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expressionbetween hepatitis B and hepatitis C leading disease progression tohepatocellular carcinoma. Hepatology, 2009, 49(4): 1098―1112

doi: 10.1002/hep.22749
Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M. Expressionand prognostic roles of the G1-S modulators in hepatocellular carcinoma:p27 independently predicts the recurrence. Hepatology, 1999, 30(1): 90―99

doi: 10.1002/hep.510300114
Jing Z, Nan K J, Hu M L. Cell proliferation, apoptosis and the related regulatorsp27, p53 expression in hepatocellular carcinoma. World J Gastroenterol, 2005, 11(13): 1910―1916
Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes H P, Odenthal M. MicroRNAgene expression profile of hepatitis C virus-associated hepatocellularcarcinoma. Hepatology, 2008, 47(4): 1223―1232

doi: 10.1002/hep.22158
Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C G, Calin G A, Giovannini C, Ferrazzi E, Grazi G L, Croce C M, Bolondi L, Negrini M. Cyclin G1 is a target ofmiR-122a, a microRNA frequently down-regulated in human hepatocellularcarcinoma. Cancer Res, 2007, 67(13): 6092―6099

doi: 10.1158/0008-5472.CAN-06-4607
Shehata M A, Nosseir H R, Nagy H M, Farouk G. Cyclindependent kinase inhibitor p27(kip1) expression and subcellular localizationin relation to cell proliferation in hepatocellualr carcinoma. Egypt J Immunol, 2006, 13(1): 115―130
Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin G A, Grazi G L, Giovannini C, Croce C M, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27(43): 5651―5661

doi: 10.1038/onc.2008.178
Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant B C, Slagle B L, Rogler L E, Zavolan M, Tuschl T, Rogler C E. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associatedhepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol, 2008, 173(3): 856―864

doi: 10.2353/ajpath.2008.080096
Su H, Yang J R, Xu T, Huang J, Xu L, Yuan Y, Zhuang S M. MicroRNA-101, down-regulated in hepatocellularcarcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 2009, 69(3): 1135―1142

doi: 10.1158/0008-5472.CAN-08-2886
Fleischer B, Schulze-Bergkamen H, Schuchmann M, Weber A, Biesterfeld S, Müller M, Krammer PH, Galle PR. Mcl-1 is ananti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol. 2006, 28(1): 25―32
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S T, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressorgene in human hepatocellular cancer. Gastroenterology, 2007, 133(2): 647―658

doi: 10.1053/j.gastro.2007.05.022
Jopling C L, Yi M, Lancaster A M, Lemon S M, Sarnow P. Modulation of hepatitis C virus RNA abundanceby a liver-specific MicroRNA. Science, 2005, 309(5740): 1577―1581

doi: 10.1126/science.1113329
Chang J, Guo J T, Jiang D, Guo H, Taylor J M, Block T M. Liver-specific microRNA miR-122 enhances the replication of hepatitisC virus in nonhepatic cells. J Virol, 2008, 82(16): 8215―8223

doi: 10.1128/JVI.02575-07
Henke J I, Goergen D, Zheng J, Song Y, Schüttler C G, Fehr C, Jünemann C, Niepmann M. MicroRNA-122 stimulates translationof hepatitis C virus RNA. EMBO J, 2008, 27(24): 3300―3310

doi: 10.1038/emboj.2008.244
Murakami Y, Aly H H, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitisC virus genome replication by miR-199a. J Hepatol, 2009, 50(3): 453―460

doi: 10.1016/j.jhep.2008.06.010
Gao Y F, Yu L, Wei W, Li J B, Luo Q L, Shen J L. Inhibition of hepatitis B virus gene expression and replication byartificial microRNA. World J Gastroenterol, 2008, 14(29): 4684―4689

doi: 10.3748/wjg.14.4684
Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P. Expressed anti-HBV primarymicroRNA shuttles inhibit viral replication efficiently in vitro andin vivo. Mol Ther, 2008, 16(6): 1105―1112

doi: 10.1038/mt.2008.82
Pedersen I M, Cheng G, Wieland S, Volinia S, Croce C M, Chisari F V, David M. Interferonmodulation of cellular microRNAs as an antiviral mechanism. Nature, 2007, 449(7164): 919―922

doi: 10.1038/nature06205
Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim M H, Filipowicz W. Decreased levels of microRNAmiR-122 in individuals with hepatitis C responding poorly to interferontherapy. Nat Med, 2009, 15(1): 31―33

doi: 10.1038/nm.1902
Georgantas R W 3rd, Hildreth R, Morisot S, Alder J, Liu C G, Heimfeld S, Calin G A, Croce C M, Civin C I. CD34+ hematopoieticstem-progenitor cell microRNA expression and function: A circuit diagramof differentiation control. Proc Natl AcadSci U S A, 2007, 104(8): 2750―2755

doi: 10.1073/pnas.0610983104
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin G A, Liu C G, Bloomfield C D, Andreeff M, Croce C M. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A, 2006, 103(13): 5078―5083

doi: 10.1073/pnas.0600587103
Rodriguez A, Vigorito E, Clare S, Warren M V, Couttet P, Soond D R, van Dongen S, Grocock R J, Das P P, Miska E A, Vetrie D, Okkenhaug K, Enright A J, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155for normal immune function. Science, 2007, 316(5824): 608―611

doi: 10.1126/science.1139253
O'Connell R M, Taganov K D, Boldin M P, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophageinflammatory response. Proc Natl Acad SciU S A, 2007, 104(5): 1604―1609

doi: 10.1073/pnas.0610731104
Ceppi M, Pereira P M, Dunand-Sauthier I, Barras E, Reith W, Santos M A, Pierre P. MicroRNA-155modulates the interleukin-1 signaling pathway in activated human monocyte-deriveddendritic cells. Proc Natl Acad Sci U SA, 2009, 106(8): 2735―2740

doi: 10.1073/pnas.0811073106
Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, Zhang H. Cellular microRNAs contributeto HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med, 2007, 13(10): 1241―1247

doi: 10.1038/nm1639
Jiang J, Lee E J, Schmittgen T D. Increased expression of mi microRNA-155 in Epstein-Barrvirus transformed lymphoblastoid cell lines. Genes Chromosomes Cancer, 2006, 45(1): 103―106

doi: 10.1002/gcc.20264
Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington E K. MicroRNA-155 is an Epstein-Barr virus-induced gene thatmodulates Epstein-Barr virus-regulated gene expression pathways. J Virol, 2008, 82(11): 5295―5306

doi: 10.1128/JVI.02380-07
Cameron J E, Yin Q, Fewell C, Lacey M, McBride J, Wang X, Lin Z, Schaefer B C, Flemington E K. Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNAmiR-146a, a modulator of lymphocyte signaling pathways. J Virol, 2008, 82(4): 1946―1958

doi: 10.1128/JVI.02136-07
Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activatesmiR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res, 2008, 36(20): 6608―6619

doi: 10.1093/nar/gkn666
Stern-Ginossar N, Elefant N, Zimmermann A, Wolf D G, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O. Host immune system gene targeting by a viral miRNA. Science, 2007, 317(5836): 376―381

doi: 10.1126/science.1140956
Dustin L B, Rice C M. Flying under the radar: theimmunobiology of hepatitis C. Annu RevImmunol, 2007, 25: 71―99

doi: 10.1146/annurev.immunol.25.022106.141602
Rehermann B, Nascimbeni M. Immunology of hepatitis Bvirus and hepatitis C virus infection. Nat Rev Immunol, 2005, 5(3): 215―229

doi: 10.1038/nri1573
Shiina M, Rehermann B. Cell culture-produced hepatitisC virus impairs plasmacytoid dendritic cell function. Hepatology, 2008, 47(2): 385―395

doi: 10.1002/hep.21996
Rigopoulou E I, Abbott W G, Williams R, Naoumov N V. Direct evidence for immunomodulatory properties of ribavirin on T-cellreactivity to hepatitis C virus. AntiviralRes, 2007, 75(1): 36―42

doi: 10.1016/j.antiviral.2006.11.008
Lu G F, Tang F A, Zheng P Y, Yang P C, Qi Y M. Entecavir up-regulates dendritic cellfunction in patients with chronic hepatitis B. World J Gastroenterol, 2008, 14(10): 1617―1621

doi: 10.3748/wjg.14.1617
Zheng P Y, Zhang D Y, Lu G F, Yang P C, Qi Y M, Wang B S. Effects of lamivudine on the function of dendritic cells derivedfrom patients with chronic hepatitis B virus infection. World J Gastroenterol, 2007, 13(34): 4641―4645
Saito T, Gale M Jr. Regulation of innate immunityagainst hepatitis C virus infection. HepatolRes, 2008, 38(2): 115―122
Ye L, Wang X, Wang S, Wang Y, Song L, Hou W, Zhou L, Li H, Ho W. CD56+ T cellsinhibit hepatitis C virus replication in human hepatocytes. Hepatology, 2009, 49(3): 753―762

doi: 10.1002/hep.22715
[1] Wenzhan Jing, Jue Liu, Min Liu. Eliminating mother-to-child transmission of HBV: progress and challenges in China[J]. Front. Med., 2020, 14(1): 21-29.
[2] Shasha Zhu, Huimin Zhang, Li Bai. NKT cells in liver diseases[J]. Front. Med., 2018, 12(3): 249-261.
[3] Kyung Im Kim, Sohyun Jeong, Nayoung Han, Jung Mi Oh, Kook-Hwan Oh, In-Wha Kim. Identification of differentially expressed miRNAs associated with chronic kidney disease–mineral bone disorder[J]. Front. Med., 2017, 11(3): 378-385.
[4] Hongli Yin,Tianyi Liu,Ying Zhang,Baofeng Yang. Caveolin proteins: a molecular insight into disease[J]. Front. Med., 2016, 10(4): 397-404.
[5] Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
[6] Feng Wang,Chen Chen,Daowen Wang. Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets[J]. Front. Med., 2014, 8(4): 404-418.
[7] Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
[8] Yong-Yuan Zhang,Ke-Qin Hu,Zhongping Duan. New perspective on the natural course of chronic HBV infection[J]. Front. Med., 2014, 8(2): 129-134.
[9] Rong Zhang, Di Wang, Zhuying Xia, Chao Chen, Peng Cheng, Hui Xie, Xianghang Luo. The role of microRNAs in adipocyte differentiation[J]. Front Med, 2013, 7(2): 223-230.
[10] Ji Qi, David Mu. MicroRNAs and lung cancers: from pathogenesis to clinical implications[J]. Front Med, 2012, 6(2): 134-155.
[11] Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG, . Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma[J]. Front. Med., 2010, 4(4): 419-429.
[12] Lei CHEN, Liang HU, Liang LI, Yuan LIU, Qian-Qian TU, Yan-Xin CHANG, He-Xin YAN, Meng-Chao WU, Hong-Yang WANG, . Dysregulation of β-catenin by hepatitis B virus X protein in HBV-infected human hepatocellular carcinomas[J]. Front. Med., 2010, 4(4): 399-411.
[13] Hong-Zhu LU MD, Dan LIU BM, Qi-Hong FAN BM, Jian-Hua ZHOU MD, . Hepatitis B virus X protein upregulates tumor necrosis factor-α expression of rat mesangial cell line via ERKs pathway[J]. Front. Med., 2010, 4(1): 106-111.
[14] Li-Feng LIU MD, PhD, Qiong CHEN MD, PhD, Ying CHANG MD, PhD, Ju-Sheng LIN MD, PhD, Jin-Liang ZHANG MM, . Cyclooxygenase-2 gene-1195G/A genotype is associated with the risk of HBV-induced HCC: A case-control study in Han Chinese people[J]. Front. Med., 2010, 4(1): 90-95.
[15] Yuanyuan LIN MD, Xiaoming CHENG MS, Yuhu SONG MD, Peiyuan LI MD, Ying CHANG MM, Jinjian YAO MD, Jusheng LIN MD, PhD, Li ZHOU PhD, Leiming XU PhD, . Construction and expression of hepatitis B virus vector encoding TC-tagged core protein[J]. Front. Med., 2009, 3(4): 396-402.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed